AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Tmunity to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 9, 2020 GMT

PHILADELPHIA--(BUSINESS WIRE)--Jan 9, 2020--

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 pm Pacific Time at the Westin St. Francis Hotel in San Francisco.

A live webcast of the presentation will be available on the “Events and Presentations” page of the Tmunity website at https://www.tmunity.com/events. Tmunity will maintain an archived replay of the webcast on the website for 30 days after the conference.

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical, and manufacturing expertise, and the demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T-cell medicine. Through the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy and other collaborations, the company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and three programs currently in clinic development. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T-cell therapies. For more information, visit www.tmunity.com and connect with us on social media at @TmunityTx and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005209/en/

CONTACT: Lisa Hayes

ir@tmunity.com

(215) 966-1600

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA PENNSYLVANIA

INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Tmunity Therapeutics, Inc.

Copyright Business Wire 2020.

PUB: 01/09/2020 07:00 AM/DISC: 01/09/2020 07:01 AM

http://www.businesswire.com/news/home/20200109005209/en